Literature DB >> 3500962

Haemophilus influenzae type b opsonins of intravenous immunoglobulins.

S Bender1, S Hetherington.   

Abstract

Immunoglobulin G may be prepared by different methods for intravenous infusion and administered as replacement therapy for hypogammaglobulinemia. Intravenous immunoglobulins prepared by different methods were compared in vitro for their ability to opsonize Haemophilus influenzae type b in the absence of complement and subsequently induce neutrophil chemiluminescence. While the antibody contents, measured by an enzyme-linked immunosorbent assay and radioimmunoassay, were equivalent, the immunoglobulin prepared by a non-molecular modifying method (ion-exchange chromatography) had the greatest ability to induce bacterial-neutrophil interaction, measured by chemiluminescence, while a reduced and alkylated immunoglobulin had the least. Thus, preparative methods may have a profound effect upon the function of intravenous immunoglobulins. The biological function of immunoglobulins for clinical use can be compared easily by neutrophil chemiluminescence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500962     DOI: 10.1007/BF00915058

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  18 in total

1.  An examination of the structural and biological properties of three intravenous immunoglobulin preparations.

Authors:  D T Law; R H Painter
Journal:  Mol Immunol       Date:  1986-03       Impact factor: 4.407

2.  Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies.

Authors:  G W Fischer; K W Hunter; V G Hemming; S R Wilson
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

3.  Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.

Authors:  J Römer; J J Morgenthaler; R Scherz; F Skvaril
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

4.  Assessment of Haemophilus influenzae type b opsonins by neutrophil chemiluminescence.

Authors:  S L Kaplan; C L Umstead; E O Mason; D C Anderson; J C Parke; R D Feigin
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

5.  Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Replacement therapy for primary immunodeficiency syndromes.

Authors:  N Kobayashi; N Gohya; S Matsumoto
Journal:  Eur J Pediatr       Date:  1981-05       Impact factor: 3.183

6.  Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus.

Authors:  K S Kim; C A Wass; J H Kang; B F Anthony
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

7.  Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; V A Barrus; G R Siber
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

8.  Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b.

Authors:  J R Schreiber; V Barrus; K L Cates; G R Siber
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

9.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

10.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

View more
  4 in total

1.  Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b.

Authors:  S V Hetherington
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

Review 2.  Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.

Authors:  S A Schwartz
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 3.  Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.

Authors:  H W Schroeder; C J Dougherty
Journal:  Infection       Date:  2012-09-12       Impact factor: 3.553

Review 4.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.